J&J’s medtech slump continues, improvements not expected until 2025

John­son & John­son beat in­vestors’ ex­pec­ta­tions de­spite its medtech unit un­der­per­form­ing, with ex­ecs point­ing to the Asia-Pa­cif­ic re­gion as a con­tin­ued source of strug­gle. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.